Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) will release its third quarter 2025 financial results on November 12, 2025. The company will host a conference call and live webcast at 9:00 AM ET to discuss results and provide a general business update.
Investors can access the live webcast on the company's Investors page at https://ir.nuwellis.com or join the call by dialing 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) using conference ID NUWEQ3. An audio archive will be posted on the Investors page after the call.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, NUWE declined 3.50%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $98K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S) or 1-203-518-9814 (international) and using the conference ID: NUWEQ3. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
For more information, visit www.nuwellis.com.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Jenene Thomas
Investor Relations
NUWE@jtcir.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
When will Nuwellis (NUWE) report third quarter 2025 results?
What time is the Nuwellis (NUWE) Q3 2025 earnings call and webcast?
How can investors access the Nuwellis (NUWE) live webcast for Q3 2025?
What phone numbers and conference ID are used to join the Nuwellis (NUWE) Q3 2025 call?
Will Nuwellis (NUWE) provide a recording of the Q3 2025 webcast?
Where can I find more information about Nuwellis (NUWE) before the November 12, 2025 call?
